2019
Pre‐transplant alpha‐fetoprotein is associated with post‐transplant hepatocellular carcinoma recurrence mortality
Mahmud N, John B, Taddei T, Goldberg DS. Pre‐transplant alpha‐fetoprotein is associated with post‐transplant hepatocellular carcinoma recurrence mortality. Clinical Transplantation 2019, 33: e13634. PMID: 31177570, PMCID: PMC6635076, DOI: 10.1111/ctr.13634.Peer-Reviewed Original ResearchConceptsHCC recurrenceLiver transplantationAlpha-fetoproteinHepatocellular carcinomaLiver diseaseHepatitis C liver diseaseEnd-stage liver diseaseC liver diseasePre-transplant modelRetrospective cohort studyOrgan Sharing databaseAdult transplant recipientsCox regression analysisTransplant recipientsCohort studySharing databaseMedian timeAFP levelsCox regressionPatient survivalUnited NetworkPoor survivalHigh riskRecurrencePatients
2018
Hepatocellular Carcinoma Outcome is Predicted by Expression of Neuronal Calcium Sensor 1
Schuette D, Moore LM, Robert ME, Taddei TH, Ehrlich BE. Hepatocellular Carcinoma Outcome is Predicted by Expression of Neuronal Calcium Sensor 1. Cancer Epidemiology Biomarkers & Prevention 2018, 27: cebp.0167.2018. PMID: 29789326, PMCID: PMC8465775, DOI: 10.1158/1055-9965.epi-18-0167.Peer-Reviewed Original ResearchConceptsNeuronal calcium sensor-1Hepatocellular carcinomaDisease outcomePrognostic biomarkerIncidence of HCCWorse disease outcomesCancer-related deathLiver cancer cohortExpression levelsFurther functional assessmentEarly tumor detectionProspective cohortAsian patientsPatient survivalVariety of Ca2Tumor microarrayHCC patientsMetastatic cancerBreast cancerCancer cohortAggressive phenotypeNovel biomarkersFunctional assessmentPredictive valueTumor progression
2017
Association of Provider Specialty and Multidisciplinary Care With Hepatocellular Carcinoma Treatment and Mortality
Serper M, Taddei TH, Mehta R, D’Addeo K, Dai F, Aytaman A, Baytarian M, Fox R, Hunt K, Goldberg DS, Valderrama A, Kaplan DE, Group V. Association of Provider Specialty and Multidisciplinary Care With Hepatocellular Carcinoma Treatment and Mortality. Gastroenterology 2017, 152: 1954-1964. PMID: 28283421, PMCID: PMC5664153, DOI: 10.1053/j.gastro.2017.02.040.Peer-Reviewed Original ResearchMeSH KeywordsAgedCarcinoma, HepatocellularChi-Square DistributionDelivery of Health Care, IntegratedFemaleGastroenterologistsHumansKaplan-Meier EstimateLiver NeoplasmsLogistic ModelsMaleMiddle AgedMultivariate AnalysisOdds RatioOncologistsPatient Care TeamPractice Patterns, Physicians'Proportional Hazards ModelsRetrospective StudiesRisk AssessmentRisk FactorsSpecializationSurgeonsTime FactorsTreatment OutcomeUnited StatesUnited States Department of Veterans AffairsConceptsRetrospective cohort studyMultidisciplinary tumor boardHealth system factorsHepatocellular carcinomaHCC therapyCohort studyOverall survivalTumor boardTime-varying Cox proportional hazards modelsCox proportional hazards modelActive hepatocellular carcinomaOutcomes of patientsProportional hazards modelHepatocellular carcinoma treatmentVeterans Administration HospitalSystem factorsLiver transplantationActive therapyLiver resectionTransarterial therapiesMedical oncologistsMultidisciplinary careSubspecialist carePatient survivalAblative therapy
2011
Successful Treatment of Fibrosing Cholestatic Hepatitis After Liver Transplantation
Cimsit B, Assis D, Caldwell C, Arvelakis A, Taddei T, Kulkarni S, Schilsky M, Emre S. Successful Treatment of Fibrosing Cholestatic Hepatitis After Liver Transplantation. Transplantation Proceedings 2011, 43: 905-908. PMID: 21486625, DOI: 10.1016/j.transproceed.2011.02.034.Peer-Reviewed Case Reports and Technical NotesConceptsLiver allograft rejectionHepatitis C virusRenal graft rejectionAllograft rejectionHCV recurrenceCholestatic hepatitisGraft rejectionHCV RNAPatient survivalEnd-stage liver disease (MELD) scoreOne-year patient survivalIFN/RBV therapyFIBROSING CHOLESTATIC HEPATITISHistologic HCV recurrenceIFN/ribavirinOne-year graftSuccessful salvage strategiesTime of OLTHCV RNA levelsLiver Disease scoreAnti-HCV therapyCohort of patientsEarly graft failureFCH groupOLT recipients